Events

T. Katsila - Exosomes facilitate the switch from innate to adaptive immunity

I. Kostopoulos - Distinct immune signatures correlate with prognostication, treatment responses...

M. Avgeris - Non-coding RNAs: Role and clinical utility in cancer immunity and immunotherapy

B. Guinn - New targets for the immunotherapeutic treatment of paediatric and adult acute...

G. Marodon - Novel immune checkpoints discovery and validation for cancer immunotherapy in mice...

G. Curigliano - Genetic determinants of immune response in breast cancer

D. Speiser - Modulation of the immune cell repertoire in breast cancer patients...

P. Papageorgis - Remodeling the tumor microenvironment to improve the efficacy of immunotherapy

J. Wischhusen - When failure is worse than giving up - Can CTL make a tumor more aggressive?

D. Mastellos - Targeting complement in cancer immunotherapy: are we closer to the bedside?

S. Brandau - MDSC activity in human cancer patients

A. Madrigal - COVID-19: Immunotherapy, Vaccines and collateral damage

P. Foukas - Predictive biomarkers for immune checkpoints inhibitors

K. Tsapakidis - Is there any role of ICIs in SCLC?

M. Tsiatas - Debate: The algorithm of first line immunotherapy in renal cancer ...